- Home
- About Us
- Our Research
- Support Us
- Why support QIMR?
- Ways you can help us
- Donate Now
- Join the Rio Tinto Ride to Conquer Cancer
- Join our Regular Giving Club
- Join the Weekend to End Women's Cancers
- Leave a bequest in your will
- Purchase Christmas cards and hampers
- Corporate partnerships
- Workplace giving
- Fundraise for QIMR
- Attend a fundraising event
- Tribute gifts
- In memoriam gifts
- Stories of hope
- Book a tour or guest speaker
- Our supporters
- Thanks to our donors
- Students
- News & Events
- Careers
- Contact Us
- QSkin
- CMV study
- Queensland Pancreatic Cancer Study
- Australian Centre for Vaccine Development
| Share on Facebook | Share on Twitter | Share on LinkedIn |
Gliomas are the most common primary brain tumour in adults and children. For patients with the commonest form, glioblastoma multiforme, the median survival is approximately one year. Gliomas have been found to be associated with human cytomegalovirus (HCMV), a common virus that usually causes flu-like symptoms upon infection, and remains dormant in the body.
If a person with HCMV becomes immunocompromised (their immune system does not work properly) through treatment or infection, the HCMV infection may reactivate.
Our research focuses on:
- Developing a vaccine for HCMV for the treatment and prevention of glioblastoma and other conditions resulting from HCMV infection.
- Manipulating a DNA repair (ATM) gene with the view to making tumours more susceptible to radiation therapies.
Our researchers have begun a Phase I trial of a vaccine to aid sufferers of glioblastoma. For more details, see the Australian New Zealand Clinical Trials Registry website.
Research laboratories involved in glioblastoma research: